Mesoblast (MESO) Accounts Payables (2015 - 2026)
Mesoblast (MESO) posted Accounts Payables of $33.6 million for Q4 2025, up 75.96% sequentially from $19.1 million in Q2 2025, and up 183.1% YoY from $11.9 million in Q4 2024.
Analysis
Mesoblast (MESO) Accounts Payables (2015 - 2026) Analysis & Trends
Mesoblast has reported Accounts Payables for 11 years, with the latest figure at $33.6 million in Q4 2025.
- Quarterly Accounts Payables rose 183.1% year-over-year to $33.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $33.6 million (up 183.1% YoY) and the FY2025 annual result came in at $19.1 million, up 169.9% from the prior year.
- Accounts Payables grew to $33.6 million in Q4 2025 per MESO's latest filing, from $19.1 million in the prior quarter.
- Over five years, Accounts Payables peaked at $33.6 million in Q4 2025 and troughed at $7.1 million in Q2 2024.
- A 5-year average of $19.1 million and a median of $19.6 million in 2021 frame the typical range for Accounts Payables.
- The sharpest annual moves came in 2024 and 2025: Accounts Payables plunged 64.9% in 2024, then soared 183.1% in 2025.
- Over 5 years, Accounts Payables stood at $20.9 million in 2021, then increased by 9.91% to $23.0 million in 2022, then sank by 53.2% to $10.8 million in 2023, then grew by 10.22% to $11.9 million in 2024, then jumped by 183.1% to $33.6 million in 2025.
- According to Business Quant data, Accounts Payables over the past three periods registered $33.6 million, $19.1 million, and $11.9 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 167.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 88.42 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 470.30 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 108.02 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 35.57 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Mesoblast | 2.24 Bn | 2.14 Bn | - | 46.81 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 46.81 Mn |
| Dec 31, 2025 | 33.58 Mn |
| Jun 30, 2025 | 19.08 Mn |
| Dec 31, 2024 | 11.86 Mn |
| Jun 30, 2024 | 7.07 Mn |
| Dec 31, 2023 | 10.76 Mn |
| Jun 30, 2023 | 20.15 Mn |
| Mar 31, 2023 | 20.97 Mn |
| Dec 31, 2022 | 22.99 Mn |
| Sep 30, 2022 | 17.66 Mn |
| Jun 30, 2022 | 23.08 Mn |
| Mar 31, 2022 | 18.98 Mn |
| Dec 31, 2021 | 20.92 Mn |
| Sep 30, 2021 | 16.26 Mn |
| Jun 30, 2021 | 19.60 Mn |
| Mar 31, 2021 | 24.28 Mn |
| Dec 31, 2020 | 28.61 Mn |
| Sep 30, 2020 | 27.60 Mn |
| Jun 30, 2020 | 24.97 Mn |
| Mar 31, 2020 | 19.48 Mn |